Regarding ex vivo analysis, other efforts to reconstruct distributions of tau pathology in 3D include efforts to analyze concordance of distributions between subjects in early AD (Ravikumar et al., 2021, Yushkevich et al., 2021, Llamas-Rodríguez et al., 2022) and to develop validation measures for in vivo molecular imaging (Ushizima et al., 2022). The gene discussed is MAPT; the disease is Alzheimer disease.